Clinical Decision Rules in the Emergency Department to Improve the Management of Acute Respiratory Infection and Acute Infectious Diarrhea
NCT ID: NCT05322694
Last Updated: 2023-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1474 participants
OBSERVATIONAL
2022-02-03
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of Bacterial and Viral Pathogens Infection Among Hospitalized Patients Feasibility Study
NCT05399615
Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms
NCT04781530
Virus Interactions in the Respiratory Tract; a Cohort Study With Children
NCT05318235
Alere i FluA*B Biologic Test Relocated in Emergency Service for Flu Diagnosis
NCT03293979
Prospective Evaluation of the Predictive Criteria of Severity for Respiratory Infection Due to COVID-19 Virus
NCT04615676
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute respiratory infections
Participants will be recruited according to their symptoms when presenting to the emergency room. They can be included either in the acute respiratory infection group or acute infectious diarrhea group or both.
Immediately after triage, eligible patients will be approached by research personnel (nurse or other professional authorized to perform the sampling and techniques required for the study) and enrolled after consent has been obtained. Once the study procedures are completed, participants will follow the care pathway that they would normally follow without the research project. The results of the clinical decision rule (molecular test and risk stratification tool) will not be disclosed to the treating team or the patient.
No interventions assigned to this group
Acute infectious diarrhea
Participants will be recruited according to their symptoms when presenting to the emergency room. They can be included either in the acute respiratory infection group or acute infectious diarrhea group or both.
Immediately after triage, eligible patients will be approached by research personnel (nurse or other professional authorized to perform the sampling and techniques required for the study) and enrolled after consent has been obtained. Once the study procedures are completed, participants will follow the care pathway that they would normally follow without the research project. The results of the clinical decision rule (molecular test and risk stratification tool) will not be disclosed to the treating team or the patient.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able to consent to the study;
3. Reachable by phone;
4. Consent to be reached directly by phone;
5. At least one of the following respiratory symptoms consistent with an acute respiratory infection for 10 days or less, i. Cough and/or ii. Purulent sputum and/or iii. Pharyngeal pain and/or iv. Nasal congestion and/or v. Rhinorrhea and/or vi. Agueusia and/or vii. Anosmia;
6. A triage score of 3 (30 minutes), 4 (60 minutes) or 5 (120 minutes) on the Canadian Triage and Acuity Scale (CTAS);
7. Triaged by the ED nurse and managed according to standard ED care protocols;
8. Resident of Québec;
9. Holder of a Québec health insurance number.
1. 18 years of age or older;
2. Able to consent to the study;
3. Reachable by phone;
4. Consent to be reached directly by phone;
5. At least three loose or liquid stools over a 24-hour period and for 10 days or less;
6. A triage score of 3 (30 minutes), 4 (60 minutes) or 5 (120 minutes) on the Canadian Triage and Acuity Scale (CTAS);
7. Triaged by the ED nurse and managed according to standard ED care protocols;
8. Resident of Québec.
9. Holder of a Québec health insurance number.
Exclusion Criteria
2. Resident of a long-term care facility;
3. Refusal of nasopharyngeal swab.
Acute infectious diarrhea :
1. Known neutropenia (\<500 neutrophils);
2. Active inflammatory bowel disease;
3. Anorectal pathology;
4. Recent colonic surgery (\< 6 months);
5. Cognitive impairment preventing the patient from reliably answering the risk stratification tool or research questions;
6. Resident of a long-term care facility;
7. Refusal of the rectal swab.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meridian Bioscience, Inc.
INDUSTRY
Ministère de l'Économie, de la Science et de l'Innovation
UNKNOWN
Simon Berthelot
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Simon Berthelot
Emergency Physician, CHU de Québec-Université Laval; Associate Professor, Faculté de médecine de l'Université Laval
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre hospitalier universitaire de Montréal
Montreal, Quebec, Canada
Hôpital Général Juif
Montreal, Quebec, Canada
CHU de Québec - Université Laval
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRI-2021-02
Identifier Type: OTHER
Identifier Source: secondary_id
FACS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.